Literature DB >> 26505926

Immunogenic properties of the surface layer precursor of Clostridium difficile and vaccination assays in animal models.

J-F Bruxelle1, A Mizrahi1, S Hoys1, A Collignon1, C Janoir1, S Péchiné2.   

Abstract

Clostridium difficile is an opportunistic pathogen causing gut inflammation generally associated with an intestinal dysbiosis due to antibiotics. Several virulence factors have been identified as playing a key role in gut colonization. The surface-layer proteins, comprised of two proteins, the high molecular weight SlpA (HMW-SLP) and the low molecular weight SlpA (LMW-SLP), are the most abundant proteins on the C. difficile surface. These two proteins are derived from the Cwp84-mediated cleavage of a single precursor protein SlpA. In this study, we assessed the immunogenic properties of a recombinant SlpA precursor derived from a toxigenic C. difficile strain (630) and its protective effect as a vaccine antigen co-administered with the cholera toxin as an adjuvant in both hamster and mouse models. First, we confirmed the immunogenicity of SlpA in humans. Sera from patients with C. difficile infection were analyzed by ELISA. Patients with CDI have a greater number of SlpA antibodies than healthy patients, confirming the immunogenicity of this protein during the pathogenic process. Then, rectal vaccination assays were performed in both conventional hamsters and mice. The animals' sera were sampled before and after vaccination, and were analyzed by ELISA. In addition, in the mouse model, feces were sampled after vaccination and IgA directed against SlpA were detected by ELISA. In both models, the intestinal colonization was evaluated by fecal bacterial count after challenge. Intra-rectal vaccination with SlpA and cholera toxin as an adjuvant induced a local and systemic humoral immune response in mice and hamsters potentially responsible for the weak decrease of C. difficile colonization in mice and the partial protection observed in a lethal-hamster model.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26505926     DOI: 10.1016/j.anaerobe.2015.10.010

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  16 in total

Review 1.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

2.  Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile.

Authors:  Jean-François Bruxelle; Assaf Mizrahi; Sandra Hoÿs; Anne Collignon; Claire Janoir; Séverine Péchiné
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

Review 3.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

4.  Influence of dairy by-product waste milk on the microbiomes of different gastrointestinal tract components in pre-weaned dairy calves.

Authors:  Y F Deng; Y J Wang; Y Zou; A Azarfar; X L Wei; S K Ji; J Zhang; Z H Wu; S X Wang; S Z Dong; Y Xu; D F Shao; J X Xiao; K L Yang; Z J Cao; S L Li
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

5.  Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune response.

Authors:  Mark Lynch; Thomas A Walsh; Izabela Marszalowska; Andrew E Webb; Micheál Mac Aogain; Thomas R Rogers; Henry Windle; Dermot Kelleher; Mary J O'Connell; Christine E Loscher
Journal:  BMC Evol Biol       Date:  2017-03-23       Impact factor: 3.260

Review 6.  Characteristics and Immunological Roles of Surface Layer Proteins in Clostridium difficile.

Authors:  Nobuaki Mori; Takashi Takahashi
Journal:  Ann Lab Med       Date:  2018-05       Impact factor: 3.464

Review 7.  Targeting Clostridium difficile Surface Components to Develop Immunotherapeutic Strategies Against Clostridium difficile Infection.

Authors:  Séverine Péchiné; Jean F Bruxelle; Claire Janoir; Anne Collignon
Journal:  Front Microbiol       Date:  2018-05-23       Impact factor: 5.640

8.  An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection.

Authors:  Gayatri Vedantam; Joshua Kochanowsky; Jason Lindsey; Michael Mallozzi; Jennifer Lising Roxas; Chelsea Adamson; Farhan Anwar; Andrew Clark; Rachel Claus-Walker; Asad Mansoor; Rebecca McQuade; Ross Calvin Monasky; Shylaja Ramamurthy; Bryan Roxas; V K Viswanathan
Journal:  Front Microbiol       Date:  2018-09-05       Impact factor: 6.064

Review 9.  Characteristics of the Clostridium difficile cell envelope and its importance in therapeutics.

Authors:  Joseph A Kirk; Oishik Banerji; Robert P Fagan
Journal:  Microb Biotechnol       Date:  2016-06-17       Impact factor: 5.813

10.  The Gut Microbiota Is Associated with Clearance of Clostridium difficile Infection Independent of Adaptive Immunity.

Authors:  Jhansi L Leslie; Kimberly C Vendrov; Matthew L Jenior; Vincent B Young
Journal:  mSphere       Date:  2019-01-30       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.